Shanghai RAAS Blood Products Co., Ltd.

SZSE:002252 Voorraadrapport

Marktkapitalisatie: CN¥48.5b

Shanghai RAAS Blood Products Toekomstige groei

Future criteriumcontroles 1/6

Shanghai RAAS Blood Products is forecast to grow earnings and revenue by 17% and 8.6% per annum respectively. EPS is expected to grow by 16.7% per annum. Return on equity is forecast to be 7.8% in 3 years.

Belangrijke informatie

17.0%

Groei van de winst

16.7%

Groei van de winst per aandeel

Biotechs winstgroei44.8%
Inkomstengroei8.6%
Toekomstig rendement op eigen vermogen7.8%
Dekking van analisten

Low

Laatst bijgewerkt28 Oct 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

SZSE:002252 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202610,1052,837N/A3583
12/31/20259,4132,572N/A4,1753
12/31/20248,5622,435N/A-2051
9/30/20248,3431,830445853N/A
6/30/20248,3161,781299797N/A
3/31/20247,9571,8181,4641,958N/A
12/31/20237,9641,7791,8272,278N/A
9/30/20237,5512,0642,0152,463N/A
6/30/20237,1742,0582,1112,394N/A
3/31/20236,9452,0512,1882,381N/A
12/31/20226,5671,8801,5001,726N/A
9/30/20226,1931,5021,0961,317N/A
6/30/20225,8261,4451,2591,488N/A
3/31/20225,1191,4161,1721,421N/A
12/31/20214,2881,2951,0891,294N/A
9/30/20213,7701,6241,3981,634N/A
6/30/20213,2081,5379421,193N/A
3/31/20212,8841,439689949N/A
12/31/20202,7621,3249171,169N/A
9/30/20202,7071,098726958N/A
6/30/20202,5978928631,066N/A
3/31/20202,7327001,0871,259N/A
12/31/20192,585608718873N/A
9/30/20192,311380554675N/A
6/30/20192,141-258433528N/A
3/31/20192,071-610299448N/A
12/31/20181,804-1,518106263N/A
9/30/20181,869-1,397116272N/A
6/30/20182,021-720N/A307N/A
3/31/20181,843-76N/A343N/A
12/31/20171,928836N/A269N/A
9/30/20172,1771,320N/A370N/A
6/30/20172,1551,673N/A381N/A
3/31/20172,2411,523N/A350N/A
12/31/20162,3261,613N/A638N/A
9/30/20162,1381,508N/A727N/A
6/30/20162,2351,259N/A788N/A
3/31/20162,1441,376N/A843N/A
12/31/20152,0131,442N/A762N/A
9/30/20151,9861,359N/A597N/A
6/30/20151,5941,169N/A431N/A
3/31/20151,422823N/A403N/A
12/31/20141,320511N/A466N/A
9/30/2014860315N/A292N/A
6/30/2014744231N/A240N/A
3/31/2014657187N/A135N/A
12/31/2013496144N/A-90N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 002252's forecast earnings growth (17% per year) is above the savings rate (2.9%).

Winst versus markt: 002252's earnings (17% per year) are forecast to grow slower than the CN market (25.8% per year).

Hoge groeiwinsten: 002252's earnings are forecast to grow, but not significantly.

Omzet versus markt: 002252's revenue (8.6% per year) is forecast to grow slower than the CN market (14% per year).

Hoge groei-inkomsten: 002252's revenue (8.6% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 002252's Return on Equity is forecast to be low in 3 years time (7.8%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y